Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it is presenting at the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts. CEO Prof. Alan Trounson will meet with senior biotech executives, business development leaders […]
Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature.
Rasa’s research thesis, titled, Re-engineering the function of natural killer cell receptors via CRISPR/Cas9: a new approach for ‘off the shelf’ immunotherapy, investigated the generation of Natural Killer (NK) cells (immune cells) from gene-edited stem cells to provide an ‘off-the-shelf’ supply for […]
Cartherics is pleased to announce that PhD Candidate, Van To, will be presenting at the Association for Cancer Immunotherapy’s 20th CIMT Annual Meeting in Germany.
CIMT is Europe’s largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As […]
Melbourne, Australia, 28 April 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]
Cartherics recently held a company offsite at the RACV Healesville Country Club and Resort. Nestled in the beautiful Yarra Valley just over an hour from Melbourne, the venue provided a relaxing escape for the Cartherics team to engage, connect and grow as individuals and a team.
We heard from motivational speakers, took part in a personal […]
Cartherics is hosting a White Shirt Day lunch on 8th May to help raise funds and awareness for ovarian cancer. The White Shirt Campaign officially launches on April 11th and culminates on White Shirt Day (8 May) – World Ovarian Cancer Day.
The campaign is a 15-year partnership between the Ovarian Cancer Research Foundation (OCRF) […]
Cartherics will be presenting at the ThymOZ 2023 International Conference on T Cells to be held from 22 -26 March at Heron Island in Queensland, Australia. The conference covers a broad range of topics including T cell differentiation and function, stromal cell biology, immunotherapy and tissue regeneration.
Rachelle Duffin, PhD Candidate at Cartherics will be presenting […]
Cartherics is pleased to announce that Dr Vera Evtimov, Project Manager and Principal Scientist, will be presenting her work in ovarian cancer research at the European Society for Medical Oncology Targeted Anticancer Therapies Congress, ESMO TAT 2023, in Paris this March.
ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading […]
Cartherics is pleased to announce that Dr Madeline Cao, Research Fellow, will be presenting at Australia Biologics 2023 at Crown Promenade, Melbourne.
The Australia Biologics Festival 2023 is Australia’s premier conference that aims to gather the innovators, pioneers, leaders in the biologics fraternity including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics […]
Melbourne, Victoria, Australia 27 February 2023
Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.
The clinical trial to be conducted by Peter Mac will be the first […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
